Biophytis unveils Phase-2 obesity trial strategy

Biophytis S.A. filed a Form 6-K to share a new clinical development update.

Accepted by SEC EDGAR 09/02/2025 - 11:05 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Biophytis S.A. filed a Form 6-K to share a new clinical development update. The company reported that it issued a press release on September 1, 2025 unveiling its Phase-2 obesity trial strategy using BIO101 in Europe and Brazil.

The press release is attached as Exhibit 99.1 to the report, providing more detail on how Biophytis plans to advance BIO101 in obesity through this Phase-2 program in those regions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biophytis (BPTS) disclose in this Form 6-K?

Biophytis S.A. disclosed that it issued a press release unveiling its Phase-2 obesity trial strategy with BIO101 in Europe and Brazil, furnished as Exhibit 99.1.

What is the main focus of Biophytis S.A.'s latest announcement?

The main focus is the unveiling of a Phase-2 obesity trial strategy involving BIO101, targeting clinical development in Europe and Brazil.

Which therapeutic area is highlighted in Biophytis (BPTS) Form 6-K?

The Form 6-K highlights Biophytis S.A.'s plans in the obesity therapeutic area through a Phase-2 clinical trial strategy with BIO101.

Where will Biophytis S.A. pursue its Phase-2 obesity trial with BIO101?

Biophytis S.A. plans to pursue its Phase-2 obesity trial strategy with BIO101 in Europe and Brazil.

What exhibit is included with Biophytis (BPTS) Form 6-K filing?

The filing includes Exhibit 99.1, which is the press release dated September 1, 2025 describing the Phase-2 obesity trial strategy with BIO101.

Who signed the Biophytis S.A. Form 6-K report?

The report was signed on behalf of Biophytis S.A. by Stanislas Veillet, Chairman and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: September 1, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On September 1, 2025, Biophytis S.A. issued a press release unveiling Phase-2 Obesity Trial Strategy with BIO101 in Europe and Brazil. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated September 1, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: September 2, 2025	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer